δ2-Opioid receptor mediation of morphine-induced CCK release in the frontal cortex of the freely moving rat

Synapse

Volumn 34, Issue 1, 1999, Pages 47-54

  Becker, Chrystel ^a   Hamon, Michel ^a   Cesselin, François ^a,b   Benoliel, Jean Jacques ^a,b  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cholecystokinin; Freely moving rat; Frontal cortex; In vivo microdialysis; Morphine; Opioid receptors

Indexed keywords

CHOLECYSTOKININ; DELTA OPIATE RECEPTOR; DELTA2 OPIATE RECEPTOR; DELTORPHIN; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTRIBEN; NALTRINDOLE; OPIATE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FRONTAL CORTEX; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT;

EID: 0033215224     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199910)34:1<47::AID-SYN6>3.0.CO;2-9     Document Type: Article

References (64)

1. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. 1991. Selective blockade of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258:299-303.
2. 1 dopamine receptor stimulation. Eur J Pharmacol 216:157-166.
3. Baber NS, Dourish CT, Hill DR. 1989. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39:307-328.
4. Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M, Cesselin F. 1991. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by K receptor stimulation. Neurosci Lett 124:204-207.
5. Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, Cesselin F. 1992. Opioid control of in vitro release of cholecystokininlike material from the rat substantia nigra. J Neurochem 58:916-922.
6. Benoliel JJ, Collin E, Mauborgne A, Bourgoin S, Legrand JC, Hamon M, Cesselin F. 1994. Mu and delta opioid receptors mediate opposite modulations by morphine of the spinal release of cholecystokininlike material. Brain Res 653:81-91.
7. Benoliel JJ, Mauborgne A, Bourgoin S, Hamon M, Cesselin F. 1997. Opioid control of CCK release from spinal cord of morphine-tolerant and non-tolerant rats. 1st European Opioid Conference, Surrey, UK, Abstract T17.
8. Buzas B, Izenwasser S, Portoghese PS, Cox BM. 1994. Evidence for delta opioid receptor subtypes regulating adenylyl cyclase activity in rat brain. Life Sci 54:101-106.
9. Carstens E, Wilson C. 1993. Rat tail flick reflex: magnitude measurement of stimulus-response function, suppression by morphine and habituation. J Neurophysiol 70:630-639.
10. Cesselin F. 1995. Opioid and anti-opioid peptides. Fundam Clin Pharmacol 9:409-433.
11. Crawley JN. 1991. Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 12:232-236.
12. 8 in the posterior part of the nucleus accumbens. Brain Res 617:181-188.
13. Derrien M, Durieux M, Roques BP. 1994. Antidepression-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br J Pharmacol 111:956-960.
14. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M. 1996. International Union of Pharmacology XII Classification of opioid receptors. Pharmacol Rev 48:567-592.
15. Di Piero V, Ferracuti S, Sabatini U, Pantano P, Cruccu G, Lenzi GL. 1994. A cerebral blood flow study on tonic pain activation in man. Pain 56:167-173.
16. Di Piero V, Fiacco F, Tombari D, Pantano P. 1997. Tonic pain: a SPECT study in normal subjects and cluster headache patients. Pain 70:185-191.
17. Dubuisson D, Dennis SG. 1977. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161-174.
18. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP. 1992. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35:2473-2481.
19. Gall C, Lauterborn J, Burks D, Seroogy K. 1987. Co-localisation of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 403:403-408.
20. Hernando F, Fuentes JA, Roques BP, Ruiz-Gayo M. 1994. The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol 261:257-263.
21. Hernando F, Fuentes JA, Ruiz-Gayo M. 1996. Impairment of stress adaptive behaviours in rats by the CCK A receptor antagonist, devazepide. Br J Pharmacol 118:400-406.
22. Hökfelt T, Skirboll L, Rehfeld JF, Goldstein M, Marley K, Dann O. 1980. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5:2093-2124.
23. 6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 257:1069-1075.
24. Jourdan D, Ardid D, Chapuy E, Eschalier A, Le Bars D. 1995. Audible and ultrasonic vocalization elicited by single electrical nociceptive stimuli to the tail in the rat. Pain 63:237-249.
25. 8 and of the CCK-B selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 628:254-262.
26. Lai J, Bilsky EJ, Rothman RB, Porreca F. 1994. Treatment with antisense oligonucleotide to the opioid delta receptor selectively inhibits delta 2-agonist antinociception. NeuroReport 5:1049-1052.
27. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. 1996. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 383:819-823.
28. 2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 258:583-587.
29. Nevo I, Becker C, Hamon M, Benoliel JJ. 1996, Stress-and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: prevention by diazepam but not ondansetron. J Neurochem 66:2041-2049.
30. 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for δ-opioid receptor heterogeneity. Neuroscience 75:917-926.
31. Paxinos P, Watson M. 1986. The rat brain in stereotaxic coordinates. Sydney: Academic Press.
32. Pelton JT, Kzamierski W, Gulya K, Yamamura HI, Hruby VJ. 1986. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for u opioid receptors. J Med Chem 29:2370-2375.
33. Portoghese PS, Sultana M, Takemori AE. 1988. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur J Pharmacol 146:185-186.
34. Portoghese PS, Sultana M, Nagase H, Takemori AE. 1992a. A highly selective δ1-opioid receptor antagonist: 7 benzylidenenaltrexone. Eur J Pharmacol 218:195-196.
35. Portoghese PS, Sultana M, Nelson WL, Klein P, Takemori AE. 1992b. δ opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for δ receptor subtypes. J Med Chem 35:4086-4091.
36. Rattray M, de Belleroche J. 1987. Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: sensitisation by naloxone. Neuropeptides 10:189-200.
37. Rodriguez RE, Sacristan MP. 1989. In vivo release of CCK-8 from the dorsal horn of the rat: inhibition by DAGOL. FEBS Lett 250:215-217.
38. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. 1993. Neutral endopeptidase 2411: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-145.
39. Roques BP, Noble F. 1995. Delta opioid related signals: relationships with CCK pathways. Analgesia 1:675-678.
40. Roques BP, Noble F. 1996. Association of enkephalin catabolism inhibitors and CCK-B antagonist: a potential use in the management of pain and opioid addiction. Neurochem Res 21:1397-1410.
41. Rothman RB. 1992. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12:129-138.
42. 3H]pBC264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 59:1805-1811.
43. Smadja C, Maldonado R, Turcaud S, Fournié-Zaluski MC, Roques BP. 1995. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalins-antidepressant-like effects. Psychopharmacology 120:400-408.
44. Sofuoglu M, Portoghese PS, Takemori AE. 1991. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analogue (NTB) in mice: evidence for delta opioid subtypes. J Pharmacol Exp Ther 257:676-680.
45. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR. 1997. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549.
46. Stanfa L, Dickenson A, Xu XJ, Wiesenfeld-Hallin Z. 1994. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 15:65-66.
47. Stengaard-Pedersen K, Larsson LI. 1981. Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system. Peptides 2(suppl 1):3-19.
48. 2 opioid receptor agonists in mice. Psychopharmacology 124:211-218.
49. Takemori AE, Portoghese PS. 1987. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in δ-funaltrexamine-treated mice. J Pharmacol Exp Ther 243:91-94.
50. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. 1988. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 243:91-94.
51. Takita M, Tsuruta T, Oh-hashi Y, Kato T. 1989. In vivo release of cholecystokinin-like immunoreactivity in rat frontal cortex under freely moving conditions. Neurosci Lett 100:249-253.
52. Tang J, Chou J, Iadarola M, Yang HYT, Costa E. 1984. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 23:715-718.
53. Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J. 1993. Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin-degrading enzymes on a model of depression in the rat. Biol Psychiatry 34:100-107.
54. Tejedor-Real P, Mico JA, Maldonado R, Roques BP. 1995. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52:145-152.
55. Tsubokawa T, Katayama Y, Ueno Y, Moriyasu N. 1981. Evidence for involvement of the frontal cortex in pain-related cerebral events in cats: increase in local cerebral blood flow by noxious stimuli. Brain Res 217:179-185.
56. Vallebuona F, Paudice P, Raiteri M. 1993. Release of cholecystokinin-like immunoreactivity in the frontal cortex of conscious rats as assessed by transcerebral microdialysis: effects of different depolarizing stimuli. J Neurochem 61:490-495.
57. Valverde O, Maldonado R, Fournié-Zaluski MC, Roques BP. 1994. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270:77-88.
58. 4]deltorphin with δ-opioid receptor subtypes in vivo. Eur J Pharmacol 252:133-137.
59. Wiesenfeld-Hallin Z, Xu XJ. 1996. The role of Cholecystokinin in nociception, neuropathic pain and opiate tolerance. Regul Pept 65:23-28.
60. Xu XJ, Elfvin A, Hao JX, Fournié-Zaluski MC, Roques BP, Wiesenfeld-Hallin Z. 1997. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level. Neuropeptides 31:287-291.
61. Zabin MA, Innis RB, Warmsley JK, Snyder SH, Kuhar MJ. 1983. Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 3:877-906.
62. Zhou Y, Sun YH, Zhang ZW, Han JS. 1993. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol 234:147-154.
63. Zimmerman DM, Leander JD. 1990. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J Med Chem 33:895-902.
64. Zouaoui D, Benoliel JJ, Conrath M, Cesselin F. 1990. Cholecystokinin-like immunoreactivity in the dorsal horn of the rat spinal cord: an attempt to analyse contradictory results between immunocytochemistry and radioimmunoassay. Neuropeptides 17:177-185.